AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2024
Jul 4, 2024
32883_dirs_2024-07-03_5ace211c-b6d5-476b-920f-fdde645a6374.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2024-07-01
Reporting Person: Radhakrishnan Karthik (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-07-01 | Stock Options | $0.7414 | A | 125000 | Acquired | 2034-06-30 | Commom Stock (125000) | Direct |
Footnotes
F1: On July 1, 2024, the reporting person was granted 125,000 stock options, vesting 6/48ths (15,625 shares) on December 31, 2024, and 1/48th every month thereafter until the stock option is fully vested on July 1, 2028.